RxDoctor Payments Data

David Mittleman, MD

Ophthalmology · West Palm Beach, FLNPI 1508818345

Payments from drug & device makers

$47,356in general payments, 2019–2025

Across 457 payments — averaging $103.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$20K
  • Bausch Health US, LLC$7K
  • Carl Zeiss Meditec USA, Inc.$4K
  • AbbVie$3K
  • Alcon Research LLC$3K
  • Sun Pharmaceutical Industries Inc.$1K
  • plus $9K from 37 others

What the payments were for

  • Consulting fees$16,50040%
  • Travel & lodging$1,8725%
  • Food & beverage$19,15547%
  • Other$3,2488%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,356 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$998,342
Medicare patients
1,679
Services billed
7,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine130$137,404
LumiganBimatoprost279$118,639
CombiganBrimonidine Tartrate/Timolol178$51,598
VyzultaLatanoprostene Bunod105$38,666
RocklatanNetarsudil Mesylat/Latanoprost70$30,873
XiidraLifitegrast39$26,979
CequaCyclosporine24$16,787
MieboPerfluorohexyloctane/Pf12$8,997
RhopressaNetarsudil Mesylate22$8,632
Cyclosporine22$7,625
Alphagan PBrimonidine Tartrate20$6,433
AzoptBrinzolamide11$4,289
SimbrinzaBrinzolamide/Brimonidine Tart14$4,172
Methazolamide11$3,284
Timolol Maleate102$2,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$3,451$314,073607 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$1,017$74,642156 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$273$39,50592 claims
Sun Pharmaceutical Industries Inc.Cequa$1,089$16,78724 claims
AlconAzopt, Simbrinza$20,478$8,46125 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$259$2,20412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →